论文部分内容阅读
目的 :观察重组人IL 2体外激活G CSF动员的健康供者外周血干细胞 ( peripheralbloodstemcell,PBSC)移植物的抗白血病细胞毒作用 ,以及rhIL 2处理对PBSC移植物造血功能的影响。方法 :细胞培养条件下 ,PBSC移植物与不同浓度rhIL 2 ( 10 0 0 ,50 0和 2 50U /ml)共培养 2 4及 72h ,采用乳酸脱氢酶 (LDH)释放法测定激活的PBSC移植物细胞毒作用 ,并应用流式细胞术分析细胞表型变化 ;采用集落形成试验测定PBSC移植物形成CFU GM、BFU E的能力。结果 :经rhIL 2体外处理的PBSC移植物 ,其细胞毒作用显著增强 ,不同rhIL 2浓度之间无显著差异 ,培养 2 4及72h则有显著差异。rhIL 2体外处理对PBSC移植物形成CFU GM、BFU E能力无抑制作用 ,且有一定的促进。结论 :提示在临床异基因外周血干细胞移植 (allo PBSCT)前 ,体外以rhIL 2处理移植物 ,可显著增强其抗白血病细胞毒作用 ;有可能在输入体内后诱导和 (或 )增强移植物抗白血病和移植物抗肿瘤效应。
OBJECTIVE: To observe the anti-leukemia cytotoxicity of peripheral blood stem cells (PBSC) mobilized by recombinant human IL-2 activated G-CSF and the effect of rhIL-2 treatment on the hematopoietic function of PBSC grafts. METHODS: PBSC grafts were cocultured with different concentrations of rhIL 2 (10 000, 50 0 and 250 U / ml) for 24 and 72 h under cell culture conditions, and activated PBSC transplantation was measured by lactate dehydrogenase (LDH) release assay Cytotoxicity was observed. Cell phenotype changes were analyzed by flow cytometry. The colony formation assay was used to determine the ability of PBSC grafts to form CFU GM and BFU E. Results: The cytotoxicity of PBSC grafts treated with rhIL 2 in vitro was significantly enhanced. There was no significant difference between the different concentrations of rhIL 2 and the difference was significant at 24 and 72 h after culture. rhIL 2 in vitro treatment of PBSC graft formation of CFU GM, BFU E ability did not inhibit, and have some promotion. CONCLUSIONS: It is suggested that rhIL 2 treatment of the graft in vitro before allogeneic peripheral blood stem cell transplantation (allo PBSCT) may significantly enhance its anti-leukemia cytotoxic effect; it is possible to induce and / or enhance graft anti- Leukemia and graft antitumor effects.